A5002754191- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Analytical Chemistry and Chromatography
- Cancer Genomics and Diagnostics
- Analytical chemistry methods development
- Mass Spectrometry Techniques and Applications
- Esophageal and GI Pathology
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Metastasis and carcinoma case studies
- Microfluidic and Capillary Electrophoresis Applications
- Marine and coastal ecosystems
- Advanced Proteomics Techniques and Applications
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- COVID-19 and healthcare impacts
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Cancer-related gene regulation
- Advanced Chemical Sensor Technologies
Renmin Hospital of Wuhan University
2020-2025
Tongji University
2024-2025
Wuhan University
2020-2025
Shanghai Pulmonary Hospital
2025
Chinese Research Academy of Environmental Sciences
2024
Eighth Affiliated Hospital of Sun Yat-sen University
2024
Sun Yat-sen University
2024
Beijing Microelectronics Technology Institute
2024
Shanghai Institute of Materia Medica
2019-2023
Chinese Academy of Sciences
2019-2023
Cross-linking mass spectrometry (XL-MS) has emerged as an attractive technology for investigating protein complexes and protein-protein interactions (PPIs). However, commonly used cross-linking strategies present significant challenges precise analysis of dynamic PPIs in native biological environments. Here we the visible-light-controlled lysine-selective (VL-XL) strategy in-depth both vitro live cells, building on light-induced primary amines o-nitrobenzyl alcohols cyclization (PANAC)...
Abstract Prostate cancer (PCa) is the second most prevalent malignancy in males across world. A greater knowledge of relationship between protein abundance and drug responses would benefit precision treatment for PCa. Herein, we establish 35 Chinese PCa primary cell models to capture specific characteristics among patients, including gene mutations, mRNA/protein/surface distributions, pharmaceutical responses. The multi-omics analyses identify Anterior Gradient 2 (AGR2) as a pre-operative...
Importance The optimal treatment for and potential benefit populations of synchronous oligometastatic esophageal squamous cell carcinoma (SOESCC) remain unclear. Objectives To evaluate outcomes concurrent chemoradiotherapy (CCRT) to construct decision tree models predicting the risk progression mortality in patients with SOESCC. Design, Setting, Participants This prognostic study included 532 SOESCC who were treated at 2 cancer centers China from January 2012 December 2018 consisted a...
Abstract In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma signet ring cell carcinoma or peritoneal metastasis, were enrolled to receive 8 cycles of apatinib, tislelizumab, and chemotherapy every 3 weeks, a maintenance therapy apatinib plus tislelizumab for maximum 1 year. Homogeneous receiving ICIs combined at the same time deemed as control group efficacy. The primary endpoint was...
<p>Supplementary Figure 2. Waterfall plot for tumor markers change is shown 33 patients who had unresectable advanced or recurrent gastric gastroesophageal junction adenocarcinoma after receiving apatinib combined with tislelizumab and chemotherapy. Increase range more than 100% considered as 100%.</p>
<p>Supplementary Figure 1. Overall survival for patients received apatinib combined with tislelizumab and chemotherapy. The median overall reached 20.9 months (95% CI: 14.60–27.20).</p>
<div>Abstract<p>In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma signet ring cell carcinoma or peritoneal metastasis were enrolled to receive eight cycles of apatinib, tislelizumab, and chemotherapy every 3 weeks, a maintenance therapy apatinib plus tislelizumab for maximum 1 year. Homogeneous receiving immune checkpoint inhibitors combined at the same time deemed as control group...
<p>Trial Protocol, and Supplementary tables</p>
<p>Supplementary Figure 6. Subscales of European Organisation for Research and Treatment Cancer QLQ-C30 questionnaire per treatment cycle. The scores were divided by 100 plotting. HRQoL = health-related quality life. We used One-way ANOVA to compare quality-of-life data different cycles, we found that patients’ life improved after treatment. (P < 0.05).</p>
<p>Supplementary Figure 4. Comparison of treatment effect between the two groups. Apatinib combined with tislelizumab and chemotherapy group (group 1), as compared ICIs 2).CR = complete response; PR partial PD progressive disease; ORR objective response rate; DCR disease control rate.</p>
<p>Supplementary Figure 5. Progression-free survival for patients received apatinib combined with tislelizumab and chemotherapy underwent surgery (Blue) or no (red).</p>
<p>Supplementary Figure 3. Baseline systemic immunity markers (NLR, ALC, PLR, and LMR), blood biomarkers(CEA, CA199, CA72–4 CA50) lipid levels(TCH,TG, LDL-Ch HDL-Ch) were not statistically associated with therapeutic response PFS. NS = No significance; ALC absolute lymphocyte count; NLC neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte LMR lymphocyte-to-monocyte TCH total cholesterol; TG triglycerides; low density lipoprotein-cholesterol; HDL-Ch high PR partial response; SD...
The efficacy of endoscopic therapy on the long-term survival outcomes T1b oesophageal cancer (EC) is unclear, this study was designed to clarify and construct a model for predicting prognosis in EC patients.
Molecular glue (MG) degraders, small molecules with significant therapeutic potential for targeting undruggable proteins, are emerging as new modality in drug discovery. Profiling the E3 ligase interactome induced by MG degraders provides insights into their mechanism of action and identifies clinically relevant neo‐substrates degradation, thereby offering opportunities. However, established methods face challenges comprehensive accurate profiling degrader‐induced interactome. Herein, we...
Combinatorial patterns of post-translational modifications (PTMs), like the histone code, play critical roles in regulating protein functionality. However, bottom-up proteomics, isobaric modification peptidoforms (IMPs) frequently co-elute and co-fragment during liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), resulting multiplexed spectra that cannot be properly analyzed by conventional identification quantification methods. Existing solutions are either limited to...
Accumulating evidence supports the existence of cancer stem cells (CSCs) in human tumors, and successful certification CSCs may lead to identification therapeutic targets, which are more effective for treatment cancer. The use spherical models has increased popularity cell investigations. Tumorospheres, used as a model established serum‑free medium supplemented with growth factors under non‑adherent conditions, one most commonly valuable method enriching CSC fraction. To investigate whether...